CORDIS
EU research results

CORDIS

English EN

Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Objective

Although vaccination is an effective way to reduce the huge disease burden associated with diarrhoea caused by enteric pathogens, many attempts to develop vaccines for shigellosis and ETEC infections have failed and a number of current approaches are too complex and costly to provide an adequate solution for LMICs. This Consortium is dedicated to advancing a radically new approach against Shigella and ETEC based not on the immunodominant, but highly variable Shigella LPS O-antigen, target of almost all past and current vaccine development efforts. There are four pillars on which the ShigETEC vaccine has been designed: (i) Elimination of the LPS O-antigen to allow recognition of multiple antigens on the cell surface that are shared among different serotypes of Shigella and are increasingly being recognized as important in protection from shigellosis. These antigens are also closely related to those of ETEC and may also help in protecting against that pathogen as well. (ii) Elimination of the invasiveness of Shigella by disruption of the invasion complex resulting in a much safer/less reactogenic oral vaccine that can take advantage of gut mucosal immunity, possibly allowing administration of high vaccine doses and therefore addresses the low immunogenicity seen with other live attenuated vaccine candidates. (iii) Addition of detoxified toxin antigens of ETEC that will induce neutralizing/blocking antibodies to these critical virulence factors. (iv) Rational molecular design of ShigETEC will allow future generations of vaccines to include additional antigens for other pathogens. The work programme entails manufacture of clinical trial material, first-in-human testing for safety and immunogenicity in non-endemic adults, a sero-epidemiology study to learn about natural immune response to the vaccine, and importantly testing the vaccine in endemic populations. The Consortium comprises partners from EU and Bangladesh that bring along highly complementary expertise.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

EUROPEAN VACCINE INITIATIVE EWIV

Address

Vossstrasse 2 Geb 4040
69115 Heidelberg

Germany

Activity type

Research Organisations

EU Contribution

€ 359 755

Participants (4)

Sort alphabetically

Sort by EU Contribution

Expand all

EVELIQURE BIOTECHNOLOGIES GMBH

Austria

EU Contribution

€ 5 024 401,62

GOETEBORGS UNIVERSITET

Sweden

EU Contribution

€ 749 842,50

INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH BANGLADESH

Bangladesh

EU Contribution

€ 1 924 713,27

PATH

United States

EU Contribution

€ 545 277,54

Project information

Grant agreement ID: 815568

Status

Ongoing project

  • Start date

    1 September 2019

  • End date

    31 August 2024

Funded under:

H2020-EU.3.1.3.

Coordinated by:

EUROPEAN VACCINE INITIATIVE EWIV

Germany